Email This Article

TheStreet Picks
Biotech Notebook: Onyx, Genentech, Cardiome
By Adam Feuerstein
02/20/08 - 06:53 AM EST
Onyx's increased spending is even more troubling than its failed Nexavar trial. Elsewhere, Genentech faces a key FDA decision.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,388.90 1,105.98 2,194.35 34.83
Oil *
77.74
UP
22.75
UP
6.06
UP
21.21
UP
1.03
10 Yr
3.48%
SPDR Gold
113.75
+0.22%
+0.55%
+0.98%
+3.05%
Data delayed 20 minutes

Brokerage Partners